Paper Details

  1. Home
  2. Paper Details

Outcomes and Management of Immune Checkpoint Inhibitor-Induced Hypothyroidism: A Retrospective Analysis.

Author: PhillipsAllison L, ReevesDavid J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study found that 19% of patients receiving immune checkpoint inhibitors (ICIs) developed clinical hypothyroidism, with a median time to onset of 13.3 weeks. Hypothyroid symptoms occurred in 34% of patients, and the median levothyroxine dose was 88 mcg (0.88 mcg/kg). Patients with clinical hypothyroidism during ICI treatment may have improved cancer outcomes, but they are more likely to develop other adverse events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Immune checkpoint inhibitors (ICIs) used in cancer treatment cause immune-related adverse effects (irAEs), including thyroiditis leading to hypothyroidism. The management and outcomes of this irAE are not well established. OBJECTIVE: The purpose of this analysis is to describe the onset...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10600280211073323

データ提供：米国国立医学図書館（NLM）

Immune Checkpoint Inhibitors and Hypothyroidism: A Balancing Act

The field of cancer treatment is constantly evolving, with new therapies emerging like desert blooms after a rare rain. Immune checkpoint inhibitors (ICIs) are a promising class of drugs that harness the power of the immune system to fight cancer. But, as with any powerful tool, they can have side effects, such as thyroiditis, which can lead to hypothyroidism, a condition where the thyroid gland doesn't produce enough hormones.

This retrospective study investigated the incidence, management, and outcomes of hypothyroidism in patients receiving ICI therapy. The researchers analyzed data from 200 patients to determine the timing of hypothyroidism onset and its impact on their cancer treatment.

Navigating the Desert of Side Effects

The study found that nearly 20% of patients developed clinical hypothyroidism during ICI treatment. While hypothyroidism can lead to fatigue and other symptoms, the researchers observed that patients who experienced hypothyroidism during ICI treatment had a longer time to disease progression, suggesting a potential benefit in terms of cancer outcomes. However, it's important to note that hypothyroidism can also increase the risk of other side effects.

Balancing the Sands of Health

The researchers recommend a starting dose of levothyroxine, a medication used to treat hypothyroidism, between 50 and 100 mcg/day for patients requiring thyroid replacement therapy. This approach aims to find the right balance between managing hypothyroidism and maximizing the benefits of ICI treatment.

Dr. Camel's Conclusion

This research highlights the complex interplay between immune checkpoint inhibitors and thyroid function. While ICI therapy can lead to hypothyroidism, this side effect might be associated with improved cancer outcomes. Careful monitoring and appropriate treatment with levothyroxine can help navigate the desert of potential side effects and achieve the best possible outcome for patients.

Date :
  1. Date Completed 2022-08-22
  2. Date Revised 2022-08-25
Further Info :

Pubmed ID

35168406

DOI: Digital Object Identifier

10.1177/10600280211073323

Related Literature

Article Analysis
・Side Effects of levothyroxine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.